Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics to Optimize Treatment in Operable Stage III and High-Risk Stage II Colon Cancer Patients

NCT06490536 is registered in ClinicalTrials.gov with IFOM ETS - The AIRC Institute of Molecular Oncology as lead sponsor.

NCT NCT06490536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06490536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics to Optimize Treatment in Operable Stage III and High-Risk Stage II Colon Cancer Patients
Lead sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
October 22, 2024
Completion date
September 1, 2028
Enrollment
700 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer stage ii, colon cancer stage iii